Loading stock data…
COR
$251.94-53.96 (-17.64%)
Market OpenUpdated 2:50 PM EDT
Cencora, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cencora, Inc. in the Healthcare sector is trading at $251.94. The stock is currently near its 52-week low of $244.82, remaining 23.1% below its 200-day moving average. Technical signals show oversold RSI of 14 and bearish MACD signal, explaining why COR maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 14) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$251.94
Potential Upside
2.2%
Whystock Fair Value$257.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$402.92+59.9%
Range$340.00 – $447.00
Fundamentals
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home hea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$59.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
37.06
Beta
Defensive asset. Lower volatility than the S&P 500.
0.72
Div Yield
Strong income play. Yield provides a meaningful total return floor.
78.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
99.42%
Volume
Today's trading volume
5.62M
Recent News
Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates
Solventum (SOLV) delivered earnings and revenue surprises of +9.36% and +1.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cencora to Report Q2 Earnings: What's in Store for the Stock?
COR heads into Q2 earnings with expected steady specialty-driven growth, but customer losses and pricing pressures could temper results.
CON vs. COR: Which Stock Is the Better Value Option?
CON vs. COR: Which Stock Is the Better Value Option?
Seeking Clues to Cencora (COR) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.